Selected article for: "anti treatment and clinical benefit"

Author: Guo-Qing Qian; Nai-Bin Yang; Feng Ding; Ada Hoi Yan Ma; Zong-Yi Wang; Yue-Fei Shen; Chun-Wei Shi; Xiang Lian; Jin-Guo Chu; Lei Chen; Zhi-Yu Wang; Da-Wei Ren; Guo-Xiang Li; Xue-Qin Chen; Hua-Jiang Shen; Xiao-Min Chen
Title: Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series
  • Document date: 2020_2_25
  • ID: jxtch47t_34
    Snippet: Currently, no anti-viral agents have been proven to be effective treatment for COVID-19. It is reported that combination of Lopinavir and Ritonavir had been applied to SARS-CoV-2 patients with substantial clinical benefit. 22 As an emerging virus, all the patients received anti-viral agents in Ningbo cohort, including Kaletra (Lopinavir/Ritonavir) and Umifenovir, 9 cases received methylprednisolone to treat high fever, SpO2 ≤93% and hypoxiemia......
    Document: Currently, no anti-viral agents have been proven to be effective treatment for COVID-19. It is reported that combination of Lopinavir and Ritonavir had been applied to SARS-CoV-2 patients with substantial clinical benefit. 22 As an emerging virus, all the patients received anti-viral agents in Ningbo cohort, including Kaletra (Lopinavir/Ritonavir) and Umifenovir, 9 cases received methylprednisolone to treat high fever, SpO2 ≤93% and hypoxiemia. The dose of methylprednisolone depends on disease severity between 1mg/kg to 2mg/kg. However, the outcome is still unclear.

    Search related documents:
    Co phrase search for related documents